Inhalation Sciences receives large order from leading company in the inhalation field
Inhalation Sciences (ISAB) has received an order for a PreciseInhale system, and DissolvIt, the system’s unique in vitro module for studying particle dissolution. The order is initially valued at approximately 2.0 MSEK.
PreciseInhale and its range of controlled aerosol exposure modules comprise a total solution for companies carrying out pre-clinical inhalation and aerosol research. DissolvIt is an in vitro module developed to characterize the dissolution rate of particles, and how this affects how a drug is absorbed in the body. DissolvIt is a unique tool. It gives companies developing inhaled medicines an exceptionally accurate early indication of how a test substance will perform in a clinical environment. DissolvIt is seen by many as the first tool that can seriously show In Vitro-In Vivo correlation (IVIVC).
“We’re delighted that the growing interest we’ve encountered in customer dialogues is now delivering concrete results. It’s also hugely significant that our unique in vitro module, DissolvIt, has received such great interest from a major player in the industry. We’ve delivered Contract Research using DissolvIt for a long time. We know that the data generated in these projects has had a big impact on our customers. This sale is a clear indication that the market is now really starting to realize the value that PreciseInhale and Inhalation Sciences delivers,” says ISAB CEO Lena Heffler.
For more information about Inhalation Sciences please contact:
Lena Heffler, CEO
Email: lena.heffler@inhalation.se
Phone: +46 (0)70 205 96 20
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.
The information above was provided by Inhalation Sciences Sweden AB (publ) according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on December 12, 2018.
Tags: